Tempest Therapeutics Stock

tempesttx.comBioTechFounded: 1900Funding to Date: $75.2MM

Tempest Therapeutics is a clinical-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.

Register for Details

For more details on financing and valuation for Tempest Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Thomas Dubensky Ph.D
Chief Executive Officer, President & Board Member
Chan Whiting Ph.D
Senior Vice President of Research & Development
Ginna Laport MD
Chief Medical Officer
Peppi Prasit Ph.D
Acting Chief Scientific Officer & Director

Board Members

Bradley Bolzon Ph.D
Versant Venture Management
Peppi Prasit Ph.D
Robert Weisskoff Ph.D
F-Prime Capital Partners
Stella Xu Ph.D
Quan Capital
Thomas Dubensky Ph.D
Tempest Therapeutics
Thomas Woiwode Ph.D
Versant Venture Management

Other companies like Tempest Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM